• 28 August, 2017
  • The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, to provide “bright lines and appropriate oversight” for regulating stem cell treatments and regenerative medicine.
    Full story
  • 28 August, 2017
  • The ISSCR Scientific Director, Heather Rooke, has accepted a position at Harvard University, and will be leaving the ISSCR on 12 September.
    Full story
  • 2 August, 2017
  • A study on the first use of CRISPR technology in the U.S. to correct a disease-causing genetic defect in early stage human embryos.
    Full story
  • Letter to Texas House of Representatives, U.S., Opposing Legislation It Says Would Put Patients at Risk

  • 6 May, 2017
  • 5/6/2017 4:00:00 AM

    The ISSCR wrote to members of the Texas House of Representatives, U.S., to oppose House Bill 661, House Bill 810, and House Bill 3236, which would allow investigational agents to be sold to patients without first providing rigorous evidence of safety and efficacy. The ISSCR believes the legislation would put patients at serious risk of harm from unproven treatments.
    Full story
  • ISSCR Opposes U.S. Ban on Federal Funding for Fetal Tissue Research - Updated 18 July, 2017

  • 17 July, 2017
  • A provision of the U.S. House of Representatives Labor-HHS-Education bill would ban federal funding for fetal tissue research.
    Full story
  • Hans Clevers Becomes President of the ISSCR

  • 13 June, 2017
  • The ISSCR is pleased to announce Hans Clevers, Hubrecht Institute, the Netherlands, as the incoming president of the ISSCR and its board of directors. Clevers assumes the post immediately following the 15th ISSCR Annual Meeting in Boston, 14-17 June, 2017.
    Full story
  • ISSCR 2017 Highlights New Discoveries in Stem Cell Research & Progress Toward Clinical Therapies

  • 25 April, 2017
  • 4/25/2017 4:00:00 AM

    Progress in stem cell research and its translation to the clinic will be the focus of the International Society for Stem Cell Research (ISSCR) annual meeting 14-17 June at the Boston Convention and Exhibition Center, Boston, Mass. More than 4,000 stem cell scientists, bioethicists, clinicians, and industry professionals from over 50 countries will share and discuss the latest discoveries and technologies within the field, and how they are advancing regenerative medicine.
    Full story
  • ISSCR Expresses Concern over FY2018 Budget Proposal in U.S.

  • 17 March, 2017
  • The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.
    Full story
  • KayeMeier

    ISSCR Announces New Policy Director

  • 20 February, 2017
  • The ISSCR has named Kaye Meier to be its new Director of Policy. Meier is responsible for directing, planning, and executing policy and advocacy efforts, enabling the society and its members to actively engage in shaping stem cell-related public policy around the world.
    Full story
  • Board Letter to Stem Cell Community Regarding Travel to ISSCR 2017

  • 10 February, 2017
  • The ISSCR Board writes a letter to the stem cell community regarding travel to the ISSCR 2017 meeting, 14-17 June.
    Full story
  • The ISSCR Opposes U.S. Administration Executive Order on Immigration

  • 30 January, 2017
  • 1/30/2017 6:00:00 AM

    The ISSCR issued a statement opposing a U.S. executive order on immigration.
    Full story
  • The ISSCR Announces 2017 Award Recipients: McEwen Award for Innovation, ISSCR Dr. Susan Lim Outstanding Young Investigator Award, ISSCR Tobias Award Lecture, and ISSCR Public Service Award

  • 23 January, 2017
  • 1/23/2017 6:00:00 AM

    The ISSCR awards recognize outstanding scientists in the field of stem cell research and regenerative medicine. Award recipients are selected by their peers, and receive the honor at the ISSCR annual meeting, where they are invited to present their science.
    Full story
  • Message from the President: Sally Temple, PhD - 2016 Year in Review

  • 13 January, 2017
  • 2016 was an eventful year in stem cell science, with significant advances that furthered understanding of regenerative systems, human biology and disease modeling, and moved forward numerous programs in clinical translation.
    Full story
  • ISSCR Convenes Nucleus Forum to Support, Advance Biomedical Investment

  • 13 January, 2017
  • The ISSCR supports investment in biomedical research that advances the stem cell and regenerative medicine fields. To underscore this commitment, the ISSCR convenes meetings of leaders in industry, technology, healthcare, and private and public foundations to discuss how to advance biomedical research and investment.
    Full story
  • Human Fetal Tissue: A Critical Resource for Biomedical Research

  • 12 January, 2017
  • Fetal tissue research has made major contributions to our understanding of biology and the development of new medical technologies, including vaccines for many diseases that have saved millions of lives. The ISSCR is providing a portfolio of examples showing how the use of fetal tissue has led to therapies that have saved lives as well as ways in which fetal tissue research continues to be necessary for medical advances.
    Full story
  • ISSCR Comments on 21st Century Cures Act in U.S.

  • 9 December, 2016
  • The ISSCR supports the increase in biomedical research funding in the 21st Century Cures Act in the U.S. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story
  • ISSCR Comments on 21st Century Cures Act Under Consideration in U.S. Congress

  • 30 November, 2016
  • The ISSCR supports the increase in biomedical research funding in the current version of the 21st Century Cures Act. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story
  • ISSCR Comments to Australian Therapeutic Goods Administration on Regulation of Autologous Cell and Tissue Products

  • 1 November, 2016
  • In comments to the Australian Therapeutic Goods Administration (TGA), the ISSCR supported regulation of autologous products that involve more than minimal manipulation of a patient’s cells and place strict limitations on the direct advertisement of cell-based therapies. The comments were in response to the TGA's call for input from interested parties about the regulation of autologous cell and tissue products.
    Full story
  • European Society of Gene and Cell Therapy & ISSCR to Present Latest in Stem Cell Research, Gene Editing and Gene Therapy 18-21 Oct., Florence IT - 30 Sept., 2016

  • 30 September, 2016
  • The European Society of Gene and Cell Therapy (ESGCT) & ISSCR host an International Symposium to Present the Latest in Stem Cell Research, Gene Editing and Gene Therapy. Latest news and developments in research will be part of the scientific programming.
    Full story
    View All ISSCR News